Description of Medical ServiceTisagenlecleucel is an autologous, murine anti-CD19 Chimeric Antigen Receptor T cell (CAR-T) therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.
Description of Medical ConditionDiffuse Large B-Cell Lymphoma (DLBCL) is an aggressive and common subtype of Non-Hodgkin Lymphoma (NHL).
Reason for ApplicationMinor changes to the MSAC eligibility criteria are requested:
- to allow TFL patients who have undergone prior autologous stem cell transplant (ASCT) to access tisagenlecleucel, without the requirement for additional systemic therapy post-ASCT; and
- that grade 3B FL patients be considered as DLBCL in the eligibility criteria due to the similarity of grade 3B FL to DLBCL in terms of presentation, behaviour and outcomes.
Medical Service TypeHybrid health technology
Previous Application Number/s1519, 1519.1
Application FormNot applicable
Consultation SurveyFeedback and comments are welcome at any stage during the MSAC process. Please provide comments on Application 1676 via a maximum of two A4 pages to HTA@health.gov.au (making sure that you type the application number at the start of your comments and in the subject heading of your email).
Public Summary DocumentPublic Summary Document (PDF 495 KB)
Public Summary Document (Word 153 KB)